Drug intelligence / Profile preview

CEP7202

Development stage: Preclinical
Lead developer: Porosome Therapeutics
Modality: Nanoparticles → Drug Delivery Systems

Overview

CEP7202 is an investigational nanoparticle-based therapeutic being developed by Porosome Therapeutics for the treatment of tumors. It utilizes the company's proprietary Porosome Nanoparticle Therapy platform, which is based on the biology of the porosome—the universal secretory machinery in cells. This platform is designed to leverage or modulate the cell's natural secretory portals to deliver therapeutic payloads or disrupt pathological secretory processes that contribute to tumor growth and progression. As of early 2024, the candidate is in the early-to-mid stages of development.

Beyond the preview

Go deeper on CEP7202.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CEP7202.

Explore the full profile